Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37870969

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2023 Nov 16
First author
Hadoux J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Hadoux J
      type
      Author
    2. name
      Elisei R
      type
      Author
    3. name
      Brose MS
      type
      Author
    4. name
      Hoff AO
      type
      Author
    5. name
      Robinson BG
      type
      Author
    6. name
      Gao M
      type
      Author
    7. name
      Jarzab B
      type
      Author
    8. name
      Isaev P
      type
      Author
    9. name
      Kopeckova K
      type
      Author
    10. name
      Wadsley J
      type
      Author
    11. name
      Führer D
      type
      Author
    12. name
      Keam B
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Hadoux J
      type
      Author
    2. name
      Elisei R
      type
      Author
    3. name
      Brose MS
      type
      Author
    4. name
      Hoff AO
      type
      Author
    5. name
      Robinson BG
      type
      Author
    6. name
      Gao M
      type
      Author
    7. name
      Jarzab B
      type
      Author
    8. name
      Isaev P
      type
      Author
    9. name
      Kopeckova K
      type
      Author
    10. name
      Wadsley J
      type
      Author
    11. name
      Führer D
      type
      Author
    12. name
      Keam B
      type
      Author
    bibliography ids
    1. nci-bib-bf7ca543e7793cc5b22cf824
    book metadata
    content sha256
    c6bf24270a698fba5dead90c17c4a74c69c186c91a35db40490f013c62097bcb
    document type
    citation
    dois
    1. 10.1056/NEJMoa2309719
    electronic publication date
    display
    2023 Oct 21
    precision
    day
    year
    2023
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:37870969
    immutable id
    pubmed:37870969@c6bf24270a698fba5dead90c17c4a74c69c186c91a35db40490f013c62097bcb
    journal
    abbreviation
    N Engl J Med
    issn electronic
    1533-4406
    issn print
    0028-4793
    issue
    20
    name
    The New England journal of medicine
    nlm unique id
    0255562
    pages
    1851-1861
    volume
    389
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      37870969
      provenance
      batch id
      6d213eecf21b6b7867cb
      provider
      NCBI PubMed ESummary
      record sha256
      d9b522b461224618d9dac00a2929d8e6ef7e382b9a16d94744c4bacf855adf69
      response sha256
      684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
      retrieved at
      2026-09-09T23:48:19.049083+00:00
      publication date
      display
      2023 Nov 16
      precision
      day
      year
      2023
      publication types
      1. Clinical Trial, Phase III
      2. Comparative Study
      3. Journal Article
      4. Randomized Controlled Trial
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/37870969/
      title
      Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

      Preserved source evidence · Not medical advice